Search

Introduction: The study of innovative drugs at the molecular, tissue, organ, systemic and organismic levels with an assessment of their safety are part of preclinical studies. In this case, studies aimed at specific pharmacological targets are especially important. The search for a selective arginase 2 inhibitor is necessary in terms of the treatment of pulmonary hypertension. One of the most common models of LH is the monocrotalin model of pulmonary hypertension. Research tasks: To evaluate the protective effects of a selective arginase 2 inhibitor, including the right ventricular contractility parameters on a monocrotalin model of pulmonary hypertension in rats. Material and Methods: A study was conducted of 5 groups of animals of 10 rats. After using a selective arginase 2 inhibitor, blood pressure, heart rate, Fulton's index, BT index, and condition of the right ventricle were evaluated. Results and Discussion: It was found that L207-0525 at doses of 1 and 3 mg/kg and tadalafil 10 mg/kg prevents the development of pulmonary hypertension. This is expressed in preventing an increase in systolic pressure in the right ventricle, Fulton, RV/BW and WT indices. L207-0525 showed a dose of 3 mg/kg for the activity shown. Conclusion: The results indicate a dose-dependent protective activity of the selective arginase 2 inhibitor L207-0525 in relation to the development of monocrotaline pulmonary hypertension. [ABSTRACT FROM AUTHOR]